Developer docs
API playgroundTry for free, no card

Search company profiles

Protein Sciences

Full company profile

uuid000dcyb

Namestring
Protein Sciences
Legal namestring
Protein Sciences Corporation
Company typeenum
Private
Founded yearint
1983
Descriptiontext

Protein Sciences Corporation is a biotechnology company founded in 1983 and headquartered in Meriden, Connecticut, that developed recombinant vaccines using proprietary baculovirus/Sf9 insect cell expression technology. Its lead product, Flublok, is an FDA-approved recombinant influenza vaccine indicated for active immunization of individuals 9 years of age and older. Flublok contains 3x the antigen content of standard-dose influenza vaccines and demonstrated 30% better protection against PCR-confirmed circulating influenza strains versus a standard-dose quadrivalent inactivated vaccine in adults 50+ in a randomized controlled trial. The cell-based recombinant production platform avoids egg-adapted mutations and allows faster manufacturing timelines than traditional egg-based methods.

Following its 2017 acquisition by Sanofi, Protein Sciences operates as part of Sanofi Pasteur, the vaccines division of the multinational pharmaceutical group. Flublok is now manufactured and distributed alongside Fluzone High-Dose (4x antigen, for adults 65+) and Fluzone (standard-dose, for persons 6 months and older) under the unified Sanofiflu brand. Revenue is generated through vaccine product sales via institutional healthcare distribution, pharmacy channels, and direct e-commerce ordering through VaccineShoppe.com, with vaccines covered by Medicare and most commercial insurers. The company serves a horizontal customer segment spanning pediatric, adult, and elderly populations with a tiered higher-dose vaccine portfolio.

The company employs 51-100 people and was led by Daniel Adams (President and CEO) and founder Steven Zimmer. Post-acquisition, Protein Sciences Corporation is no longer independently traded, and its operations are fully integrated into Sanofi's commercial and manufacturing infrastructure.

Short descriptiontext

Protein Sciences Corporation developed Flublok, a recombinant influenza vaccine using baculovirus insect cell expression technology. Founded in 1983 in Meriden, Connecticut, and acquired by Sanofi in 2017, it now operates as part of Sanofi Pasteur's Sanofiflu vaccine franchise.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMeriden, United States
HQ citystring
Meriden
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
recombinant influenza vaccines, vaccine biotechnology, baculovirus expression technology, biologics manufacturing, flu vaccines
Industry3 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Influenza Vaccines
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Vaccine product sales
TypeOne Time License
Description

Revenue generated from sale of influenza vaccines (Flublok) through healthcare distribution channels, covered by Medicare and commercial insurance plans.

pro.campus.sanofi
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Medicare and commercial insurance covered vaccines
ModelOtherBilling cadencePay-as-you-go
Notes

Covered by Medicare and most commercial insurers

pro.campus.sanofi
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Flublok
Description

Recombinant influenza vaccine developed by Protein Sciences Corporation using baculovirus expression technology. Now manufactured and distributed by Sanofi Pasteur Inc.

pro.campus.sanofi
Core offering1 text field

Protein Sciences develops and manufactures recombinant influenza vaccines using proprietary baculovirus expression vector technology in insect cells. Its principal product is a recombinant trivalent/quadrivalent influenza vaccine produced without the use of eggs, intended for adults seeking flu immunization. Following acquisition by Sanofi in 2017, the company operates as part of Sanofi Pasteur.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 30% better protection against influenza due to any PCR-confirmed circulating strains vs standard-dose quadrivalent inactivated influenza vaccine in adults 50 years of age and older
Product overview1 text field

Protein Sciences, now part of Sanofi, offers a portfolio of influenza vaccines under the Sanofiflu brand. The portfolio includes three vaccine products: Flublok (recombinant influenza vaccine, approved for persons 9 years and older, containing 3x antigen content), Fluzone High-Dose (approved for persons 65 years and older, containing 4x antigen content), and Fluzone (standard-dose, approved for persons 6 months and older). These are trivalent/quadrivalent vaccines for active immunization against influenza A and B virus subtypes. The higher-dose formulations (Flublok and Fluzone High-Dose) are proven in randomized controlled trials to provide superior protection in older adults compared to standard-dose vaccines.

Product and service1 record
1Flublok Quadrivalent
CategoryInfluenza vaccine
Description

Flublok is a recombinant quadrivalent influenza vaccine approved for adults 18 years and older. It is manufactured using a baculovirus expression vector system (BEVS) in Sf9 insect cells rather than egg-based production, enabling faster manufacturing and avoiding egg-derived protein. Each dose contains 45 micrograms of hemagglutinin per strain (180 µg total) and is FDA-approved.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Develops influenza vaccines (including ABFCell cellular technology and mRNA programs) and is a major US flu competitor. A broad incumbent whose flu offerings overlap Flublok's target market.

2Sanofi Pasteur
TypeDirect peer
Description

Parent entity of Protein Sciences and operator of the Sanofiflu franchise (Flublok, Fluzone, Fluzone High-Dose). It is the most directly comparable competitor-distributor in seasonal influenza vaccines globally.

TypeEmerging player
Description

Vaccine-focused biotech with viral vector and recombinant capabilities. Comparable as a smaller specialty vaccine company developing biological platform vaccines for infectious diseases.

TypeBroad incumbent
Description

Major vaccine incumbent with influenza products (Fluarix, Flulaval) and broad vaccine portfolio. Competes against Flublok in the same seasonal flu market but operates across many other vaccine categories.

TypeEmerging player
Description

Smaller vaccine biotech with VLP and enveloped virus platforms targeting infectious disease. Comparable as a platform-vaccine peer focused on differentiated recombinant/virus-like particle approaches.

TypeDirect peer
Description

Direct competitor in cell-based and recombinant influenza vaccines (Flucelvax). Seqirus also operates a major egg-based portfolio and competes with Flublok in the same US adult and older-adult segments through similar distribution channels.

TypeDirect peer
Description

Uses recombinant protein nanoparticle technology (Matrix-M adjuvant) to produce vaccines. Shares the recombinant protein-subunit paradigm with Flublok and is a directly comparable biologics-platform vaccine peer.

TypeOthers
Description

Vaccine adjuvant and recombinant hepatitis B vaccine (Heplisav-B) company. Adjacent peer supplying enabling vaccine technology and competing for share in adult immunization channels that also buy Flublok.

TypeEmerging player
Description

Developing mRNA-based seasonal and pandemic influenza vaccines. Represents the next-generation platform risk to recombinant and egg-based flu vaccines such as Flublok.

TypeEmerging player
Description

CDMO and vaccine developer with biologics manufacturing capabilities. Operates in adjacent vaccine/biodefense space and shares scale, regulatory complexity, and biologics manufacturing characteristics with Protein Sciences.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Protein Sciences

Influenza Vaccinesproteinsciences.com

Protein Sciences Corporation developed Flublok, a recombinant influenza vaccine using baculovirus insect cell expression technology. Founded in 1983 in Meriden, Connecticut, and acquired by Sanofi in 2017, it now operates as part of Sanofi Pasteur's Sanofiflu vaccine franchise.

What Protein Sciences does

Protein Sciences Corporation is a biotechnology company founded in 1983 and headquartered in Meriden, Connecticut, that developed recombinant vaccines using proprietary baculovirus/Sf9 insect cell expression technology. Its lead product, Flublok, is an FDA-approved recombinant influenza vaccine indicated for active immunization of individuals 9 years of age and older. Flublok contains 3x the antigen content of standard-dose influenza vaccines and demonstrated 30% better protection against PCR-confirmed circulating influenza strains versus a standard-dose quadrivalent inactivated vaccine in adults 50+ in a randomized controlled trial. The cell-based recombinant production platform avoids egg-adapted mutations and allows faster manufacturing timelines than traditional egg-based methods.

Following its 2017 acquisition by Sanofi, Protein Sciences operates as part of Sanofi Pasteur, the vaccines division of the multinational pharmaceutical group. Flublok is now manufactured and distributed alongside Fluzone High-Dose (4x antigen, for adults 65+) and Fluzone (standard-dose, for persons 6 months and older) under the unified Sanofiflu brand. Revenue is generated through vaccine product sales via institutional healthcare distribution, pharmacy channels, and direct e-commerce ordering through VaccineShoppe.com, with vaccines covered by Medicare and most commercial insurers. The company serves a horizontal customer segment spanning pediatric, adult, and elderly populations with a tiered higher-dose vaccine portfolio.

The company employs 51-100 people and was led by Daniel Adams (President and CEO) and founder Steven Zimmer. Post-acquisition, Protein Sciences Corporation is no longer independently traded, and its operations are fully integrated into Sanofi's commercial and manufacturing infrastructure.

Protein Sciences firmographics

Firmographics
Name
Protein Sciences
Legal name
Protein Sciences Corporation
Website
https://proteinsciences.com
Company type
Private
Founded year
1983
Operating status
Acquired
Headcount range
11–50 employees
Short description
Protein Sciences Corporation developed Flublok, a recombinant influenza vaccine using baculovirus insect cell expression technology. Founded in 1983 in Meriden, Connecticut, and acquired by Sanofi in 2017, it now operates as part of Sanofi Pasteur's Sanofiflu vaccine franchise.
Ownership category
akta.pro rank

Protein Sciences industry classification

Industry
Product category
Influenza Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Recombinant influenza vaccines
  • Vaccine biotechnology
  • Baculovirus expression technology
  • Biologics manufacturing
  • Flu vaccines

Where Protein Sciences is headquartered

Location

Headquarters

HQ city
Meriden
HQ country
United States
HQ region
North America

Markets served

Protein Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Vaccine product sales: Revenue generated from sale of influenza vaccines (Flublok) through healthcare distribution channels, covered by Medicare and commercial insurance plans.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goMedicare and commercial insurance covered vaccines

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Protein Sciences product offering

Product offering

Core offering

Protein Sciences develops and manufactures recombinant influenza vaccines using proprietary baculovirus expression vector technology in insect cells. Its principal product is a recombinant trivalent/quadrivalent influenza vaccine produced without the use of eggs, intended for adults seeking flu immunization. Following acquisition by Sanofi in 2017, the company operates as part of Sanofi Pasteur.

Product overview

Protein Sciences, now part of Sanofi, offers a portfolio of influenza vaccines under the Sanofiflu brand. The portfolio includes three vaccine products: Flublok (recombinant influenza vaccine, approved for persons 9 years and older, containing 3x antigen content), Fluzone High-Dose (approved for persons 65 years and older, containing 4x antigen content), and Fluzone (standard-dose, approved for persons 6 months and older). These are trivalent/quadrivalent vaccines for active immunization against influenza A and B virus subtypes. The higher-dose formulations (Flublok and Fluzone High-Dose) are proven in randomized controlled trials to provide superior protection in older adults compared to standard-dose vaccines.

Differentiator

Problem solved

Functional benefit

Brands

  • Flublok: Recombinant influenza vaccine developed by Protein Sciences Corporation using baculovirus expression technology. Now manufactured and distributed by Sanofi Pasteur Inc.

Products and services

  • Flublok Quadrivalent Flublok is a recombinant quadrivalent influenza vaccine approved for adults 18 years and older. It is manufactured using a baculovirus expression vector system (BEVS) in Sf9 insect cells rather than egg-based production, enabling faster manufacturing and avoiding egg-derived protein. Each dose contains 45 micrograms of hemagglutinin per strain (180 µg total) and is FDA-approved.

Quantifiable outcome

  • 30% better protection against influenza due to any PCR-confirmed circulating strains vs standard-dose quadrivalent inactivated influenza vaccine in adults 50 years of age and older

Companies that use Protein Sciences

Customer profile

Segments1 record

Ideal customer profiles1 record

Protein Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Protein Sciences partnerships and signals

Strategic signal

Scale indicators1 record

Expansion highlights4 records

Protein Sciences competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Develops influenza vaccines (including ABFCell cellular technology and mRNA programs) and is a major US flu competitor. A broad incumbent whose flu offerings overlap Flublok's target market.
  • GSK: Major vaccine incumbent with influenza products (Fluarix, Flulaval) and broad vaccine portfolio. Competes against Flublok in the same seasonal flu market but operates across many other vaccine categories.

Direct peers

  • Sanofi Pasteur: Parent entity of Protein Sciences and operator of the Sanofiflu franchise (Flublok, Fluzone, Fluzone High-Dose). It is the most directly comparable competitor-distributor in seasonal influenza vaccines globally.
  • CSL Seqirus: Direct competitor in cell-based and recombinant influenza vaccines (Flucelvax). Seqirus also operates a major egg-based portfolio and competes with Flublok in the same US adult and older-adult segments through similar distribution channels.
  • Novavax: Uses recombinant protein nanoparticle technology (Matrix-M adjuvant) to produce vaccines. Shares the recombinant protein-subunit paradigm with Flublok and is a directly comparable biologics-platform vaccine peer.

Emerging players

  • Bavarian Nordic: Vaccine-focused biotech with viral vector and recombinant capabilities. Comparable as a smaller specialty vaccine company developing biological platform vaccines for infectious diseases.
  • VBI Vaccines: Smaller vaccine biotech with VLP and enveloped virus platforms targeting infectious disease. Comparable as a platform-vaccine peer focused on differentiated recombinant/virus-like particle approaches.
  • Moderna: Developing mRNA-based seasonal and pandemic influenza vaccines. Represents the next-generation platform risk to recombinant and egg-based flu vaccines such as Flublok.
  • Emergent BioSolutions: CDMO and vaccine developer with biologics manufacturing capabilities. Operates in adjacent vaccine/biodefense space and shares scale, regulatory complexity, and biologics manufacturing characteristics with Protein Sciences.

Others

  • Dynavax Technologies: Vaccine adjuvant and recombinant hepatitis B vaccine (Heplisav-B) company. Adjacent peer supplying enabling vaccine technology and competing for share in adult immunization channels that also buy Flublok.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Protein Sciences social profiles

Digital presence

Protein Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Protein Sciences leadership team

Management profile

Number of profiles

Protein Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Protein Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Protein Sciences

What does Protein Sciences do?

Protein Sciences develops and manufactures recombinant influenza vaccines using proprietary baculovirus expression vector technology in insect cells. Its principal product is a recombinant trivalent/quadrivalent influenza vaccine produced without the use of eggs, intended for adults seeking flu immunization. Following acquisition by Sanofi in 2017, the company operates as part of Sanofi Pasteur.

Is Protein Sciences a public or private company?

Protein Sciences is a private company. It is classified as corporate owned and is currently acquired.

When was Protein Sciences founded?

Protein Sciences was founded in 1983. It employs 11 to 50 people.

Where is Protein Sciences based?

Protein Sciences is headquartered in Meriden, United States, in the North America region.

How does Protein Sciences make money?

One revenue line is on record: vaccine product sales.

Who are Protein Sciences's main competitors?

Broad incumbents on record are Pfizer and GSK. Direct peers are Sanofi Pasteur, CSL Seqirus and Novavax. Emerging players are Bavarian Nordic, VBI Vaccines, Moderna and Emergent BioSolutions. Dynavax Technologies is listed as an others.

Does Protein Sciences have an API?

No public API is recorded for Protein Sciences.

What industry is Protein Sciences in?

Protein Sciences's product category is Influenza Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Hartford Business JournalFormer Protein Sciences CEO Cox takes top job at Seattle biotechDr. Manon Cox will become CEO of Seattle's AVM Biotechnology, a startup developing drugs for Non-Hodgkin's Lymphoma. She previously led Protein Sciences, which sold to Sanofi for $750 million in 2017. AVM's first clinical trial of AVM0703-001 is currently enrolling patients.PR NewswireAVM Biotechnology's Executive Leadership Team Joined by Dr. Manon Cox, MBA, former Protein Sciences Corporation CEO and Dr. Gary Grohmann, former Australian Regulatory OfficialAVM Biotechnology announced the appointment of Dr. Manon Cox as CEO and Dr. Gary Grohmann as Chief Regulatory Officer to its executive leadership team. The company is currently enrolling patients in a clinical trial for its lead drug, AVM0703, targeting relapsed or refractory Non-Hodgkin's Lymphoma.news.cision.comDiamyd Medical enters agreement to facilitate transition of manufacturingDiamyd Medical and Protein Sciences Corporation agreed to transition the manufacturing of recombinant GAD65, the active ingredient in Diamyd, to a new manufacturer. PSC will provide $5 million in cash, raw materials, and up to 150 man-hours of technical assistance, with payment in the first quarter of 2020.news.cision.comDiamyd Medical’s manufacturing process may be moved to a new manufacturerDiamyd Medical's CEO and founder informed Protein Sciences that the company cannot meet Diamyd Medical's manufacturing needs for rhGAD65 under a 2017 Purchase Agreement. Protein Sciences offered to support a transition to a new manufacturer, with details to be discussed. Diamyd Medical's diabetes vaccine Diamyd has shown safety in trials with over 1,000 patients.PR NewswireGlobal Influenza Vaccines Market 2018-2024: Market is Anticipated to Exceed US$ 5.8 Billion with bioCSL, GSK, Novartis, Protein Sciences, Sanofi Pasteur & Seqirus DominatingThe global influenza vaccines market is projected to exceed $5.8 billion by 2024, with North America holding over 48% of the market in 2017. The United States leads country-wise, and Sanofi's Fluzone holds the largest brand share. Growth is driven by low vaccination coverage in emerging markets and rising awareness, though supply shortages due to viral strain variation remain a restraint.PR NewswireGlobal Influenza Vaccines Market 2018-2024: Market is Anticipated to Exceed US$ 5.8 Billion with bioCSL, GSK, Novartis, Protein Sciences, Sanofi Pasteur & Seqirus DominatingA market research report projects the global influenza vaccines market will exceed US$5.8 billion by 2024, driven by low vaccination coverage in emerging markets, new vaccine introductions, and rising government support, though supply shortages due to viral strain variability present a restraint. North America held over 48% of the market in 2017, with the United States remaining the largest national market, followed by Japan, China, Brazil, and India. Notable strategic transactions include Sanofi's acquisition of Protein Sciences in August 2017 and SK Chemicals' $155 million licensing agreement with Sanofi Pasteur for universal influenza vaccine development in February 2018.PR NewswireGlobal Influenza Vaccines Market, Persons Vaccinated, Brand Analysis, Size, Share, Growth, Trends, Major Deals - Forecast to 2024The global influenza vaccines market is projected to exceed US$5.8 billion by 2024, driven by low vaccination coverage in emerging markets, new vaccine introductions, and rising government support for immunization programs. North America held the largest regional share at over 48% in 2017, with the United States, Japan, and China representing the top three national markets. Key strategic transactions in the sector include SK Chemicals signing a $155 million licensing deal with Sanofi Pasteur in February 2018 for cell culture technology, and Sanofi completing its acquisition of Protein Sciences in August 2017.PR NewswireFlu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024Bharat Book Bureau has published a market research report projecting the United States flu vaccine market will reach nearly US$ 3 billion by 2024, driven by increased disease awareness, expanded vaccination recommendations, and introduction of quadrivalent flu vaccines. The report identifies Sanofi Pasteur, GSK, and Seqirus as major players in the US flu vaccine market, with GSK flu vaccine sales projected to reach approximately US$ 1.5 billion by 2024. Additional highlights include Sanofi's planned acquisition of Protein Sciences Corporation and BiondVax's positive Phase 2b clinical trial results for its universal flu vaccine.FinSMEsSanofi Acquires Protein Sciences, for Up To $750M - FinSMEsSanofi completed the acquisition of Protein Sciences, a Meriden, Connecticut-based vaccines biotechnology company. The deal includes a $650 million upfront payment and up to $100 million upon milestone achievement, adding Flublok, a recombinant influenza vaccine, to Sanofi Pasteur's portfolio. The acquisition supports Sanofi's initiative to explore non-egg-based influenza vaccine manufacturing.GlobeNewswireSanofi completes the acquisition of Protein SciencesSanofi completed its acquisition of Protein Sciences, a biotech that developed Flublok Quadrivalent, a recombinant influenza vaccine. The deal includes a $650 million upfront payment and up to $100 million in milestone payments. The acquisition aligns with Sanofi's strategy to expand non-egg-based vaccine manufacturing.